QP 19 - GI 4: Quick Pitch: Enhancing Efficacy for Esophageal cancer and Radiation Reponders for Rectal Cancer

Presentations

• 08:00am - 09:00am PT

  GI 4: Quick Pitch: Enhancing Efficacy for Esophageal cancer and Radiation Reponders for Rectal Cancer

  Speaker: Julie Koenig, MD - Mass General Brigham, Somerville
• 08:00am - 09:00am PT

  GI 4: Quick Pitch: Enhancing Efficacy for Esophageal cancer and Radiation Reponders for Rectal Cancer

  Speaker: Hyun Kim, MD - Washington University School of Medicine, St. Louis
• 08:10am - 08:15am PT

  Radiotherapy followed by Systemic Therapy and Tislelizumab in MSS Rectal Cancer with Unresectable Metastases: Results of the MIRACLE-2 Study

  Speaker: Zhen Zhang, MD, PhD - Fudan University Shanghai Cancer Center, shanghai
• 08:05am - 08:10am PT

  Short-Term Radiotherapy Plus Chemotherapy increased the T downstaging rates compared to Long-Term Chemoradiotherapy in Low-Lying LocallyAdvanced Rectal Cancer: A post-hoc analysis of the STELLAR Trial

  Speaker: Junqin Lei, MD - National Cancer Center CAMS & PUMC, Beijing
• 08:10am - 08:15am PT

  Treatment Outcomes and Prognostic Factors in Young-Onset Rectal Cancer

  Speaker: Daniel Hong, MD - Washington University in St. Louis, St. Louis
• 08:20am - 08:25am PT

  Peripheral Blood Immune Cell Dynamics as Indicators and Predictors of Clinical Response to Immunotherapy Based Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

  Speaker: Yingxuan Lin, MD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Shanghai
• 08:25am - 08:30am PT

  Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial

  Speaker: Yujin Xu, MD, PhD - Zhejiang Cancer Hospital, Hangzhou
• 08:30am - 08:35am PT

  Endoscopic Ultrasound Fine Needle Injection of NBTXR3 Activated by Radiotherapy with Concurrent Chemotherapy for Adenocarcinoma of the Esophagus: Feasibility and Safety of the Phase I Dose Escalation

  Speaker: Steven Lin, MD, PhD - The University of Texas MD Anderson Cancer Center, Houston
• 08:15am - 08:20am PT

  Genetic Variants and Immunotherapy-Combined Modality Correlates with Neoadjuvant Therapy Outcomes in Microsatellite-Stable Rectal Cancer

  Speaker: Lijie Zhang, - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai